Kodiak Sciences Inc. has announced promising results from their Phase 1 clinical trial of KSI-301, a novel anti-VEGF compound for the treatment of age-related macular degeneration, retinal vein occlusion, and diabetic macular edema.
Currently approved anti-VEGF drugs require several monthly “loading dosages” at the beginning of the treatment regimen. Twelve weeks after a single dose of KSI-301, however, improvement of almost two lines (9 eye chart letters) and retinal edema of 121 microns were achieved across all three dose levels tested.
A multiple-dose Phase 1b study in patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion is now recruiting patients. “We believe that, if successful, a regimen which provides nearly all patients with a 12-week or better treatment interval would be unique and industry-leading”, said Victor Perlroth, M.D., Kodiak’s Chief Executive Officer. “We remain on track for [Phase 2] to begin enrollment in the second quarter of 2019.”
KSI-301 is the newest of several experimental drugs that are designed to increase the time between injections, thereby easing the treatment burden on patients. Read about other candidates.
Source: Kodiak Press Release